Document Detail


Efficacy of venom immunotherapy given every 3 or 4 months: a prospective comparison with the conventional regimen.
MedLine Citation:
PMID:  23244659     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
BACKGROUND: Standard venom immunotherapy involves the administration of the maintenance dose every 4 to 6 weeks. This regimen may have adherence problems, especially in the long term; thus, extended intervals have been proposed.
OBJECTIVE: We prospectively compared the efficacy of 3- or 4-month extended maintenance dose vs the conventional regimen.
METHODS: Patients receiving immunotherapy with a single venom were offered the extended maintenance dose (EMD) and were then followed up for field re-stings. Only the re-stings by the insect for which the patients received immunotherapy were considered. A comparable group of patients receiving the conventional maintenance dose (CMD) was used for comparison by logistic regression analysis.
RESULTS: Seventy-six patients (60 male; mean age, 48 years) receiving the EMD were re-stung on 247 occasions by the insect for which they were receiving immunotherapy. The group receiving CMD included 110 patients (82 male; mean age, 44 years) certainly re-stung on 167 occasions by the specific insect. The percentage of re-sting without reaction was 93.5% in the EMD group and 81.5% in the CMD group, with a significant difference in favor of the former (P=.001). At logistic regression analysis, only age, but not maintenance dose protocol, was predictive of subsequent systemic reactions.
CONCLUSION: The EMD is as effective and safe as the CMD. An increased maintenance seems to be the best option in term of convenience and economic savings.
Authors:
Livio Simioni; Alberto Vianello; Patrizia Bonadonna; Guido Marcer; Maurizio Severino; Mauro Pagani; Luca Morlin; Mariangiola Crivellaro; Giovanni Passalacqua
Related Documents :
19605849 - First-line therapy with fludarabine compared with chlorambucil does not result in a maj...
16424649 - Randomized trial of anti-d immunoglobulin versus low-dose intravenous immunoglobulin in...
6278169 - The clinical relevance of 'csf viral culture'. a two-year experience with aseptic menin...
11159509 - Long-term use of anagrelide in young patients with essential thrombocythemia.
9407939 - Pulsed high-dose dexamethasone therapy in children with chronic idiopathic thrombocytop...
8808719 - Recombinant human granulocyte-macrophage colony-stimulating factor (rhugm-csf) in leuko...
8981889 - Hybrid total hip arthroplasty: 7- to 10-year results.
7338579 - Comparative efficacy and safety of bumetanide and furosemide in long-term treatment of ...
8523349 - Total hip arthroplasty in patients with ankylosing spondylitis: longterm followup.
Publication Detail:
Type:  Journal Article     Date:  2012-10-11
Journal Detail:
Title:  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology     Volume:  110     ISSN:  1534-4436     ISO Abbreviation:  Ann. Allergy Asthma Immunol.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2012-12-18     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9503580     Medline TA:  Ann Allergy Asthma Immunol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  51-4     Citation Subset:  IM    
Copyright Information:
Copyright © 2013 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Affiliation:
Allergy and Clin. Immunology, Internal Medicine Department, "S. Maria del Prato" Feltre Hospital, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Association of Toll-like receptor 2 gene polymorphisms with lung function in workers in swine operat...
Next Document:  Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell...